{'52WeekChange': 0.5845071,
 'SandP52WeekChange': None,
 'address1': 'River Oaks Tower',
 'address2': 'Suite 1200 3730 Kirby Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 7.91,
 'askSize': 3100,
 'averageDailyVolume10Day': 205350,
 'averageVolume': 178292,
 'averageVolume10days': 205350,
 'beta': 3.507002,
 'beta3Year': None,
 'bid': 7.9,
 'bidSize': 800,
 'bookValue': 3.929,
 'category': None,
 'circulatingSupply': None,
 'city': 'Houston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 9.14,
 'dayLow': 7.91,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.252,
 'enterpriseToRevenue': 24.579,
 'enterpriseValue': 75063104,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 12.088858,
 'fiftyTwoWeekHigh': 15.62,
 'fiftyTwoWeekLow': 3.34,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 9633325,
 'forwardEps': -1.95,
 'forwardPE': -4.0564103,
 'fromCurrency': None,
 'fullTimeEmployees': 16,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.31344998,
 'heldPercentInstitutions': 0.41689998,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1539648000,
 'lastSplitFactor': '1:6',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/aravive.com',
 'longBusinessSummary': 'Aravive, Inc., a clinical-stage biopharmaceutical '
                        'company, develops treatments for life-threatening '
                        'diseases. Its lead product candidate is AVB-500, a '
                        'decoy protein that targets the GAS6-AXL signaling '
                        'pathway, which is in Phase Ib/II clinical trial for '
                        'the treatment of platinum- resistant recurrent '
                        'ovarian cancer, as well as for the treatment of clear '
                        'cell renal cell carcinoma, triple negative breast '
                        'cancer, acute myeloid leukemia, and pancreatic '
                        'cancer. The company has a strategic collaboration '
                        'agreement with WuXi Biologics to develop novel '
                        'high-affinity bispecific antibodies targeting cancer '
                        'and fibrosis. The company was formerly known as '
                        'Versartis, Inc. and changed its name to Aravive, Inc. '
                        'in October 2018. Aravive, Inc. is headquartered in '
                        'Houston, Texas.',
 'longName': 'Aravive, Inc.',
 'market': 'us_market',
 'marketCap': 126529936,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_59516531',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -24310000,
 'nextFiscalYearEnd': 1640908800,
 'open': 9.14,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.02,
 'phone': '936 355 1910',
 'previousClose': 9,
 'priceHint': 2,
 'priceToBook': 2.0132349,
 'priceToSalesTrailing12Months': 41.43089,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 9.14,
 'regularMarketDayLow': 7.91,
 'regularMarketOpen': 9.14,
 'regularMarketPreviousClose': 9,
 'regularMarketPrice': 9.14,
 'regularMarketVolume': 279945,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 15996200,
 'sharesPercentSharesOut': 0.0552,
 'sharesShort': 883426,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 338002,
 'shortName': 'Aravive, Inc.',
 'shortPercentOfFloat': 0.0717,
 'shortRatio': 4.04,
 'startDate': None,
 'state': 'TX',
 'strikePrice': None,
 'symbol': 'ARAV',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.941,
 'twoHundredDayAverage': 10.40813,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '436420eb-ae2d-3616-84a1-4664b78d3c14',
 'volume': 279945,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://aravive.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '77098'}